Acute Effects of E-3174, a Human Active Metabolite of Losartan, on the Cardiovascular System in Tachycardia-Induced Canine Heart Failure

この論文にアクセスする

この論文をさがす

著者

    • SUZUKI Jun
    • Pharmacology, Tsukuba Research Institute, Banyu Pharmaceutical, Co., Ltd.
    • OHTA Hisashi
    • Pharmacology, Tsukuba Research Institute, Banyu Pharmaceutical, Co., Ltd.
    • HANADA Kayoko
    • Pharmacology, Tsukuba Research Institute, Banyu Pharmaceutical, Co., Ltd.
    • KAWAI Nobuko
    • Pharmacology, Tsukuba Research Institute, Banyu Pharmaceutical, Co., Ltd.
    • IKEDA Takanori
    • Pharmacology, Tsukuba Research Institute, Banyu Pharmaceutical, Co., Ltd.
    • NAKAO Mizuki
    • Pharmacology, Tsukuba Research Institute, Banyu Pharmaceutical, Co., Ltd.
    • IKEMOTO Fumihiko
    • Pharmacology, Tsukuba Research Institute, Banyu Pharmaceutical, Co., Ltd.
    • NISHIKIBE Masaru
    • Pharmacology, Tsukuba Research Institute, Banyu Pharmaceutical, Co., Ltd.

抄録

The aim of this study was to evaluate the acute effects of E-3174, a human active metabolite of the AT1 receptor antagonist, losartan, on hemodynamic functions in dogs with severe heart failure (HF). In dogs, insignificant plasma levels of E-3174 are present following administration of losartan, and therefore, the effects of these two drugs can be studied independently in the dog. HF was established by rapid pacing of the right ventricle (250-270 beats/min) for 4 weeks. We examined changes in cardiovascular functions after acute intravenous administration of losartan (1mg/kg) and E-3174 (0.3 and 1mg/kg), as well as an ACE inhibitor, enalapril (0.3 and 1mg/kg), under condition of HF. The HF before treatment was characterized by increases in pre- and after-load of the left ventricle (LV), consequent low cardiac output, and LV dilatation. E-3174 at 0.3 and 1mg/kg reduced pulmonary artery pressure (−13±6% and −22±3% from baseline, respectively, <I>p</I><0.05), pulmonary capillary wedge pressure (−18±4% and −36±10%, <I>p</I><0.05) and mean arterial pressure (−24±2% and −36±7%, <I>p</I><0.05), increased stroke volume (SV: +12±7% <I>p</I>>0.05; +36±19%, <I>p</I><0.05), and reduced peripheral resistance (−23±5% and −41±9%, <I>p</I><0.05), but had no effect on the first derivative of left ventricular pressure (dP/dt/P) or the time constant for relaxation. Effects of losartan at 1mg/kg were similar to those of 0.3mg/kg of E-3174. Enalapril at 1mg/kg caused changes comparable to those seen after E-3174 administration (1mg/kg), except that the increase in SV (+16±8%, <I>p</I><0.05) with enalapril was not as great as that with E-3174. Both losartan at 1mg/kg and E-3174 at 0.3 and 1mg/kg increased fractional shortening to a similar extent (FS: +52±12%, +47±8% and +56±8%), while enalapril at 0.3 and 1mg/kg had no significant effects on FS. Reflex elevation of plasma renin activity induced by 1mg/kg of E-3174 was similar to that caused by 1mg/kg of enalapril, suggesting that the two drugs achieved similar inhibition of the endogenous renin angiotensin system. Our study demonstrated that acute blockade of the AT1 receptor with E-3174 reduced elevated pre- and after-load and consequently increased stroke volume in a canine HF model. With the exception of changes in stroke volume, these effects of E-3174 were comparable to those produced by enalapril, and were 3 times stronger than those by losartan. (Hypertens Res 2001; 24: 65-74)

収録刊行物

  • Hypertension research : clinical and experimental : official journal of the Japanese Society of Hypertension

    Hypertension research : clinical and experimental : official journal of the Japanese Society of Hypertension 24(1), 65-74, 2001-01-01

    The Japanese Society of Hypertension

参考文献:  37件中 1-37件 を表示

各種コード

  • NII論文ID(NAID)
    10008742078
  • NII書誌ID(NCID)
    AA10847079
  • 本文言語コード
    ENG
  • 資料種別
    ART
  • ISSN
    09169636
  • データ提供元
    CJP書誌  J-STAGE 
ページトップへ